PLUSClinical Trialsglobenewswire

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Sentiment:Positive (80)

Summary

REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 18, 2025 by globenewswire